Resverlogix Corp.

Location:

300 4820 Richard Road SWCalgaryAlbertaT3E 6L1Canada View Map

Revenue:

$303,000

Employees:

27

SIC Codes:

2834, 2835

NAICS Codes:

325412,

Phone:

(403) 254-9252

Fax:

(403) 256-8495
More

Description:

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Read More

Competitors

Recently Updated profiles at this company

Senior Clinical Research Associate

Senior Vice President Clinical Development

President and Chief Executive Officer

Senior Vice President Medical Affairs

Senior Vice President Business and Corporate Development

Applied Research Scientist

Browse ZoomInfo’s Directories